' 
![]()
SCIENTIFIC SCORE
Likely Very Effective
Based on 2 Researches
9
USERS' SCORE
Good
Based on 8 Reviews
8.9
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Iron (elemental) (from 180 mg Ferrous Bisglycinate)(Ferrochel™)
36 mg
200%
Top Medical Research Studies
9
Macrophage EVs combat iron overload
Macrophage-derived extracellular vesicles represent a promising endogenous iron-chelating therapy for iron overload and cardiac injury in myocardial infarction.
Direct relevance to iron treatment
We delved into the connection between iron overload and its effects on heart function after a heart attack, also known as myocardial infarction (MI). Our research focused on utilizing macrophage-derived extracellular vesicles (EVs) as a natural therapy to help with excessive iron levels in the heart.
The downside of existing chemical iron chelators is that they often come with side effects, so we sought a safer and more effective solution. By isolating EVs from macrophages, we found that they serve as a biological chelator for iron. When we introduced these EVs to heart cells affected by low oxygen levels, they significantly reduced iron overload and minimized the oxidative stress linked to this excess iron.
Notably, these EVs work by harnessing a receptor called transferrin receptor (TfR), which helps them grab onto and remove the surplus protein-bound iron. In our observations, when the EVs lacked TfR, they were ineffective in protecting heart tissue. This shows that leveraging macrophage-derived EVs could offer a new approach in treating heart damage due to iron overload, especially after myocardial infarction.
The downside of existing chemical iron chelators is that they often come with side effects, so we sought a safer and more effective solution. By isolating EVs from macrophages, we found that they serve as a biological chelator for iron. When we introduced these EVs to heart cells affected by low oxygen levels, they significantly reduced iron overload and minimized the oxidative stress linked to this excess iron.
Notably, these EVs work by harnessing a receptor called transferrin receptor (TfR), which helps them grab onto and remove the surplus protein-bound iron. In our observations, when the EVs lacked TfR, they were ineffective in protecting heart tissue. This shows that leveraging macrophage-derived EVs could offer a new approach in treating heart damage due to iron overload, especially after myocardial infarction.
Read More
9
Iron reduces mortality in AMI
Association of Iron Therapy with Mortality in Patients with Acute Myocardial Infarction and Iron Deficiency.
Strong relevance to heart health
We explored the role of iron therapy in patients suffering from acute myocardial infarction (AMI), particularly those with iron deficiency. This interesting study analyzed data from the Medical Information Mart in Intensive Care-IV database, focusing on patients admitted to an intensive care unit between 2008 and 2019.
After carefully categorizing patients based on their exposure to iron treatment, we performed a thorough statistical analysis to highlight any differences in outcomes. The primary focus was on 28-day mortality rates, and the results were telling. In a group of 208 patients who received either iron treatment or no treatment, those receiving iron had significantly lower death rates—8.65% compared to 20.19% in the untreated group.
This finding suggests that iron therapy could play a crucial role in improving survival in AMI patients with iron deficiency. While it did not affect how long patients stayed in the hospital or the ICU, the potential for reduced mortality is promising. However, we recognize that more prospective studies are needed to fully verify these conclusions and understand the broader implications for treatment.
After carefully categorizing patients based on their exposure to iron treatment, we performed a thorough statistical analysis to highlight any differences in outcomes. The primary focus was on 28-day mortality rates, and the results were telling. In a group of 208 patients who received either iron treatment or no treatment, those receiving iron had significantly lower death rates—8.65% compared to 20.19% in the untreated group.
This finding suggests that iron therapy could play a crucial role in improving survival in AMI patients with iron deficiency. While it did not affect how long patients stayed in the hospital or the ICU, the potential for reduced mortality is promising. However, we recognize that more prospective studies are needed to fully verify these conclusions and understand the broader implications for treatment.
Read More
Most Useful Reviews
9.5
Improved hemoglobin levels
The rescue! Three years ago, I struggled with treating my anaemia; my haemoglobin was stuck at 80. After taking this specific iron supplement for two years, my haemoglobin is now consistently 140. I no longer experience the headaches I used to, nor am I freezing like before. This product is irreplaceable for me.
Read More
9.5
Essential for women's health
I've been using this supplement to combat anaemia and boost ferritin levels. In Japan, I found the local iron supplements had poor absorption. This product has been essential for my health, particularly during menstruation and potential pregnancy. Since starting it, my dizziness and heart pains have vanished.
Read More
9.5
Eliminated heart issues
This iron dietary supplement was indispensable during my pregnancy. I took one capsule daily with vitamin C, which contributed to the disappearance of my long-standing arrhythmia and tachycardia. My hair loss ceased, and my overall well-being improved. No side effects were noted; I highly recommend it!
Read More
Medical Researches
SCIENTIFIC SCORE
Likely Very Effective
Based on 2 Researches
9
9
Macrophage EVs combat iron overload
Macrophage-derived extracellular vesicles represent a promising endogenous iron-chelating therapy for iron overload and cardiac injury in myocardial infarction.
Direct relevance to iron treatment
We delved into the connection between iron overload and its effects on heart function after a heart attack, also known as myocardial infarction (MI). Our research focused on utilizing macrophage-derived extracellular vesicles (EVs) as a natural therapy to help with excessive iron levels in the heart.
The downside of existing chemical iron chelators is that they often come with side effects, so we sought a safer and more effective solution. By isolating EVs from macrophages, we found that they serve as a biological chelator for iron. When we introduced these EVs to heart cells affected by low oxygen levels, they significantly reduced iron overload and minimized the oxidative stress linked to this excess iron.
Notably, these EVs work by harnessing a receptor called transferrin receptor (TfR), which helps them grab onto and remove the surplus protein-bound iron. In our observations, when the EVs lacked TfR, they were ineffective in protecting heart tissue. This shows that leveraging macrophage-derived EVs could offer a new approach in treating heart damage due to iron overload, especially after myocardial infarction.
The downside of existing chemical iron chelators is that they often come with side effects, so we sought a safer and more effective solution. By isolating EVs from macrophages, we found that they serve as a biological chelator for iron. When we introduced these EVs to heart cells affected by low oxygen levels, they significantly reduced iron overload and minimized the oxidative stress linked to this excess iron.
Notably, these EVs work by harnessing a receptor called transferrin receptor (TfR), which helps them grab onto and remove the surplus protein-bound iron. In our observations, when the EVs lacked TfR, they were ineffective in protecting heart tissue. This shows that leveraging macrophage-derived EVs could offer a new approach in treating heart damage due to iron overload, especially after myocardial infarction.
Read More
9
Iron reduces mortality in AMI
Association of Iron Therapy with Mortality in Patients with Acute Myocardial Infarction and Iron Deficiency.
Strong relevance to heart health
We explored the role of iron therapy in patients suffering from acute myocardial infarction (AMI), particularly those with iron deficiency. This interesting study analyzed data from the Medical Information Mart in Intensive Care-IV database, focusing on patients admitted to an intensive care unit between 2008 and 2019.
After carefully categorizing patients based on their exposure to iron treatment, we performed a thorough statistical analysis to highlight any differences in outcomes. The primary focus was on 28-day mortality rates, and the results were telling. In a group of 208 patients who received either iron treatment or no treatment, those receiving iron had significantly lower death rates—8.65% compared to 20.19% in the untreated group.
This finding suggests that iron therapy could play a crucial role in improving survival in AMI patients with iron deficiency. While it did not affect how long patients stayed in the hospital or the ICU, the potential for reduced mortality is promising. However, we recognize that more prospective studies are needed to fully verify these conclusions and understand the broader implications for treatment.
After carefully categorizing patients based on their exposure to iron treatment, we performed a thorough statistical analysis to highlight any differences in outcomes. The primary focus was on 28-day mortality rates, and the results were telling. In a group of 208 patients who received either iron treatment or no treatment, those receiving iron had significantly lower death rates—8.65% compared to 20.19% in the untreated group.
This finding suggests that iron therapy could play a crucial role in improving survival in AMI patients with iron deficiency. While it did not affect how long patients stayed in the hospital or the ICU, the potential for reduced mortality is promising. However, we recognize that more prospective studies are needed to fully verify these conclusions and understand the broader implications for treatment.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.9
9.5
Improved hemoglobin levels
The rescue! Three years ago, I struggled with treating my anaemia; my haemoglobin was stuck at 80. After taking this specific iron supplement for two years, my haemoglobin is now consistently 140. I no longer experience the headaches I used to, nor am I freezing like before. This product is irreplaceable for me.
Read More
9.5
Significant health improvement
This iron supplement helped me immensely. My iron levels were at 13 in December and dropped to 2 by March, leading to heart issues and constant dizziness. After switching to this product, I began feeling better, and my iron levels are now 13. I recommend it highly.
9.5
Essential for women's health
I've been using this supplement to combat anaemia and boost ferritin levels. In Japan, I found the local iron supplements had poor absorption. This product has been essential for my health, particularly during menstruation and potential pregnancy. Since starting it, my dizziness and heart pains have vanished.
Read More
9.5
Eliminated heart issues
This iron dietary supplement was indispensable during my pregnancy. I took one capsule daily with vitamin C, which contributed to the disappearance of my long-standing arrhythmia and tachycardia. My hair loss ceased, and my overall well-being improved. No side effects were noted; I highly recommend it!
Read More
9.5
Fantastic for anaemia
My brother has heart problems, so we opted for this supplement. It’s fantastic for blood health, especially for those who are anaemic. Unlike typical iron supplements that can cause constipation or heavy bleeding, this product didn't, and I will definitely purchase it again.
